MétaCan
Menu
Back to cohort
Record W1995904050 · doi:10.1086/605431

Use of Peroxisome Proliferator‐Activated Receptor γ Agonists as Adjunctive Treatment for <i>Plasmodium falciparum</i> Malaria: A Randomized, Double‐Blind, Placebo‐Controlled Trial

2009· article· en· W1995904050 on OpenAlexafffund
Andrea K. Boggild, Srivicha Krudsood, Samir N. Patel, Lena Serghides, Noppadon Tangpukdee, Kevin Katz, Polrat Wilairatana, W. Conrad Liles, Sornchai Looareesuwan, Kevin C. Kain

Bibliographic record

VenueClinical Infectious Diseases · 2009
Typearticle
Languageen
FieldMedicine
TopicMalaria Research and Control
Canadian institutionsNorth York General HospitalUniversity of TorontoUniversity Health NetworkToronto General Hospital
FundersCanada Research ChairsCanadian Institutes of Health ResearchGenome CanadaOntario GenomicsOntario Genomics InstituteUniversity of WashingtonGlaxoSmithKline
KeywordsMalariaMedicineRosiglitazoneAdjunctive treatmentPlasmodium falciparumCase fatality ratePlaceboImmunologyArtemisininPeroxisome proliferator-activated receptorPharmacologyInternal medicineReceptorEpidemiologyPathology

Abstract

fetched live from OpenAlex

BACKGROUND: Despite the use of potent antimalarial drugs, the fatality rate associated with severe malaria remains high. Adjunctive therapies that target the immunopathological responses to infection may decrease mortality associated with severe malaria. We hypothesized that peroxisome proliferator-activated receptor gamma agonists (eg, rosiglitazone) would modulate the host's innate immune response to malaria and improve outcome. METHODS: In a randomized, double-blind, placebo-controlled, phase I/II trial of treatment for malaria acquired in Thailand, we investigated the safety, tolerability, and efficacy of rosiglitazone use for parasite clearance and for reducing malaria-induced inflammation. Sequential patients with uncomplicated Plasmodium falciparum malaria were randomly assigned to 1 of 2 groups: 70 patients received rosiglitazone 4 mg twice daily for 4 days, and 70 patients received a placebo twice daily for 4 days. Both groups also received standard antimalarial therapy (ie, a fixed combination of 1000 mg of atovaquone per day for 3 days and 400 mg of proguanil per day for 3 days). Primary efficacy outcomes were 50% and 90% parasite clearance times (PCTs). Secondary outcomes were fever clearance time, levels of inflammatory mediators, blood glucose measurements, aminotransferase levels, admission to intensive care, and subjective tolerability of study drug. RESULTS: For the 70 patients who received rosiglitazone, parasite clearance from peripheral blood was significantly enhanced, compared with the 70 patients who received a placebo (mean 50% PCT, 19.0 h vs. 24.6 h [p = .029]; mean 90% PCT, 30.9 h vs. 40.4 h [p = .004]). Also, the patients who received rosiglitazone had reduced inflammatory responses to infection, compared with the patients who received a placebo (ie, interleukin-6 levels at 24 h [p < .005] and at 48 h [p = .013] and monocyte chemoattractant protein-1 level at 48 h [p = .05]). There were no significant differences between the 2 groups with regard to safety and tolerability of treatment, and there were no admissions the intensive care unit or deaths. CONCLUSIONS: The use of rosiglitazone is a well-tolerated adjunct to standard therapy for nonsevere P. falciparum malaria. Treatment with rosiglitazone increased parasite clearance and decreased inflammatory biomarkers associated with adverse malaria outcomes. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT00149383 .

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.010
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch, Meta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.033
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.010
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0040.003
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.068
GPT teacher head0.381
Teacher spread0.313 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations72
Published2009
Admission routes2
Has abstractyes

Explore more

Same venueClinical Infectious DiseasesSame topicMalaria Research and ControlFrench-language works237,207